Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 5/12/2019
SIETES contiene 92850 citas

 1 a 20 de 29 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
2.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
3. Cita con resumen
Anónimo. Cataractes d'origine médicamenteuse. Prescrire 2010;30:743-6. [Ref.ID 89216]
4. Cita con resumen
Naughton C. Drug-induced nephrotoxcicity. American Family Physician 2008;78:743-50. [Ref.ID 87065]
6.Tiene citas relacionadas Cita con resumen
Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CMB, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MKB, on behalf of the MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685-94. [Ref.ID 82947]
7.Tiene citas relacionadas
Vogelzang NJ. Chemotherapy for malignant pleural mesothelioma. Lancet 2008;371:1640-2. [Ref.ID 82937]
Anónimo. Les pneumopathies interstitielles dues à des médicaments. Prescrire 2007;27:510-2. [Ref.ID 80442]
9.Tiene citas relacionadas
Argiris A, Schiller JH. Can current treatments for advanced non-small-cell lung cancer be improved?. JAMA 2004;292:499-500. [Ref.ID 70883]
10.Tiene citas relacionadas Cita con resumen
Delbado C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon J-P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer. A meta-analysis. JAMA 2004;292:470-84. [Ref.ID 70882]
Anónimo. Management of pancreatic cancer. Drug Ther Bull 2003;41:36-40. [Ref.ID 66008]
12. Cita con resumen
Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002;25:301-11. [Ref.ID 61985]
13.Tiene citas relacionadas Cita con resumen
Medina PJ, George JN. Drug-associated blood dyscrasias. Adv Drug React Bull 2001;210:803-6. [Ref.ID 60750]
Kintzel PE. Anticancer drug-induced kidney disorders: incidence, prevention and management. Drug Saf 2001;24:19-38. [Ref.ID 59615]
Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf 2001;24:491-501. [Ref.ID 57152]
Anónimo. Purpura thrombotique thrombopénique dû au médicament. Prescrire 2000;20:835-6. [Ref.ID 54536]
Sparano JA, Wolff AC, Brown D. Troponins for predicting cardiotoxicity from cancer therapy. Lancet 2000;356:1947-8. [Ref.ID 54360]
Khaw PT, Cordiero MF. Towards better treatment of glaucoma. BMJ 2000;320:1619-20. [Ref.ID 51539]
Pai VP, Nahata M C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302. [Ref.ID 50164]
Highley MS, van Oosterom AT, Mes RA, de Bruijn EA. Intravesical drug delivery: pharmacokinetic and clinical considerations. Clin Pharmacokinet 1999;37:59-73. [Ref.ID 46103]
Seleccionar todas
 1 a 20 de 29 siguiente >>